The Peptide CommonsEst. May 2024
Search
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
PS

p.silva

TL2 Moderator · Poznań

Contributes reviews on supplier material. Based in Poznań.

Joined 27 March 2025 · last posted 5d

90Posts here
1Topics
0Solutions
810Likes received
608Likes given
19Badges
197Days visited
3.4kPosts read

Recent activity

Full stream
  • Pinch or no pinch, and how needle length changes the answer — what changed since Replied, post #61 · Practice › Administration · 23 Jul 2026 · 2 likes Picking up post #58: that is the part I would want checked first. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the…
  • Coming back to: Telehealth prescribing models in the US Replied, post #25 · Regional › North America · 23 Jul 2026 · 0 likes This follows post #22 rather than contradicting it. United States: FDA licenses compounds. Prescribing and pharmacy practice are state-regulated. Compounds are…
  • Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #44 · Compounds › Repair & healing peptides · 21 Jul 2026 · 0 likes Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no…
  • Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #90 · Evidence › Journal club · 20 Jul 2026 · 0 likes SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes. The first outcome trial in people without diabetes, which decoupled the cardiovascular…
  • Revisiting: What pooling buys you and what it destroys Replied, post #98 · Evidence › Meta-analyses · 20 Jul 2026 · 0 likes Picking up post #95: that is the part I would want checked first. Subgroup analysis: sometimes a meta-analysis reports separate pooled estimates for different subgroups…
  • NHS criteria and how they are applied in practice Replied, post #35 · Regional › UK & Ireland · 19 Jul 2026 · 0 likes post #34 answers the question as asked. The question underneath it is different. Importing for personal use: importing a prescription-only medicine without a…
  • Documenting a supplier's response to a discrepancy Replied, post #35 · Sourcing › Vendor reports · 10 Jul 2026 · 1 like Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
  • Pooling trials with different estimands Replied, post #63 · Evidence › Meta-analyses · 1 Jul 2026 · 0 likes This follows post #60 rather than contradicting it. Publication bias: what did not get published? Small studies with negative results are less likely to be published…
  • [2026 update] Area percent versus weight percent: the confusion that causes most arguments Replied, post #62 · Analytics › HPLC & UHPLC · 24 Jun 2026 · 3 likes Worth separating two things that post #58 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
  • Insurance and replacement policies, compared Replied, post #32 · Sourcing › Logistics · 20 Jun 2026 · 2 likes Import restrictions by jurisdiction: what is legal to import for personal use varies enormously by country. Some jurisdictions are quite permissive; others are not.…
  • Follow-up: Search filters: what is missing Replied, post #134 · Meta › Site feedback · 20 Jun 2026 · 17 likes On post #130 — agreed on the reasoning, with one qualification. Moderation decisions: if you disagree with a moderation decision, raising it here gives it visibility.…
  • A site rotation scheme that is easy enough to actually follow — a second dataset Started this topic · Practice › Administration · 18 Jun 2026 · 0 likes A site rotation scheme that is easy enough to actually follow — a second dataset Writing it up because I had to work it out twice and would rather nobody else did.…